Ocular surface disease (OSD) is a
significant problem for glaucoma patients worldwide, who will require long-term
topical treatment. The risk of OSD increases with age, with a reportedprevalence of up to 60%.
The severity and burden of OSD also increase with the
number of topical anti-glaucoma medications used in treatment due to multiple,
daily exposures of the ocular surface (OS) to toxic active compounds in the
drug itself, other components of the formulation or preservatives. Thepresentation of OSD varies depending on its severity, but usually includessymptoms of dry eyes, allergy and distorted vision, which can be debilitatingand affect quality of life. The clinical signs of the disease include tear-film
instability, toxic kerato conjunctivitis, eyelid abnormalities and allergic
manifestations. However, the lack of concordance between symptoms and signs
often makes the diagnosis of OSD and assessment of its severity challenging.
No comments:
Post a Comment